Gilead Sciences Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for their HIV treatment, Biktarvy. The approval expands the use of Biktarvy to include people with HIV who have a history of antiretroviral treatment, are not virologically suppressed, and are restarting therapy. This new indication addresses a significant public health need by offering a treatment option for individuals who have interrupted their HIV care and are not currently achieving viral suppression. The decision was based on robust evidence from studies demonstrating Biktarvy's effectiveness in achieving rapid and durable viral suppression, as well as its strong safety profile.